Mannkind Corporation

Becton Dickinson and Company Limited

Bio-plexus, Inc.

Smith + Nephew

Bio-plexus Delaware, Inc.

P Spencer Kinsey

Chad C Smutney

Benoit Adamo

John M Polidoro

Carl R Sahi

Dennis Overfield

Scott McLean

Brendan F Laurenzi

Anthony Bryant

Kenneth G Powell

Richard G Holdaway

David Schoch Chapin

Daniel McMichael Stipe

Vincent J Sullivan

Matthew S Ferriter

Ge Jiang

Mark T Marino

Christine Billings

Scott Mclean

Kelly Sullivan Kraft

Karla Somerville

David S Chapin

Richard D Nelson

Charles D Shermer

Alexander George Lastovich

Petter Hedstrom

Daniel M Stipe

James Fentress

Alfred Mann

Timothy J Morrill

Jeff M Moss

Melody Kuroda

Marius Walter Hauri

Tom He

Gregory Melville

Ed Browka

Anthony J Bryant

Dennis O Overfield

Grayson Walker Stowell

Marshall L Grant

Paul Menkin

Joseph J Guarneri

Gregory F Biancardi

Dennis Overfiled

Gary L Edmond

Douglas A Racicot

Walter Hauri

Dennis Overfileld

Jeff Moss

James K Fentress

Joseph Guarneri

Brendan Laurenzi

John J Pocreva Iii

A breath-powered, dry powder inhaler, a cartridge, and a pulmonary drug delivery system are provided.

Dry powder inhaler and system for drug delivery

A breath-powered, dry powder inhaler, a cartridge, and a pulmonary drug delivery system are provided. The dry powder inhaler can be provided with or without a unit dose cartridge for using with the inhaler. The inhaler and/or cartridge can be provided with a drug delivery formulation comprising, for example, a diketopiperazine and an active ingredient, including, peptides and proteins such as insulin, oxyntomodulin and glucagon-like peptide.

A pulmonary drug delivery system is disclosed, including a breath-powered, dry powder inhaler, with or without a cartridge for delivering a dry powder formulation. The inhaler and cartridge can be provided with a drug delivery formulation comprising, for example, a diketopiperazine and an active ingredient, including, small organic molecules, peptides and proteins, including, hormones such as insulin and glucagon-like peptide 1 for the treatment of disease and disorders, for example, diseases and disorders, including endocrine disease such as diabetes and/or obesity.

Dry powder drug delivery system and methods

Described herein are interactive apparatus and methods for sensing and measuring real-time characteristic patterns of a subject's use of a dry powder inhalation system. The devices can be used in a wired or wireless communication mode to communicate with a display to assess the subject's usage of the inhalation system, to evaluate the performance of the inhalation system and/or to detect the characteristics profile of a dry powder formulation emitted from the inhalation system in use.

Interactive apparatus and method for real-time profiling of inhalation efforts

A breath-powered, dry powder inhaler, a cartridge, and a pulmonary drug delivery system are provided. The dry powder inhaler can be provided with or without a unit dose cartridge for using with the inhaler. The inhaler and/or cartridge can be provided with a drug delivery formulation comprising, for example, a diketopiperazine and an active ingredient, including, peptides and proteins such as insulin and glucagon-like peptide 1 for the treatment of diabetes and/or obesity. The dry powder inhaler is compact; can be provided in various shapes and sizes, colors, and comprises a housing, a mouthpiece, a cartridge placement area, and a mechanism for opening and closing the medicament cartridge. The device is easy to manufacture, provides a pre-metered single unit dose, it is relatively easy to use, and can be reusable or disposable.

A mouthpiece cover for an inhaler is described. The mouthpiece cover is designed for use with a dry powder inhaler and is provided with structural features to prevent a patient from inhaling the cover.

Mouthpiece cover for an inhaler

A pulmonary drug delivery system is disclosed, including a breath-powered, dry powder inhaler, and a cartridge for delivering a dry powder formulation. The inhaler and cartridge can be provided with a drug delivery formulation comprising, for example, a diketopiperazine and an active ingredient, including, peptides and proteins such as insulin and glucagon-like peptide 1 for the treatment of endocrine disease, for example, diabetes and/or obesity.

Dry powder drug delivery system

Inhaler

Growing community of inventors

Sandy Hook, CT, United States of America

P Spencer Kinsey